Assignee
AVEO PHARMACEUTICALS INC
US·31 granted patents·21 pending applications·150 citations·filing 2004–2025
Top patents by PatentIndex Score
52 records- 0195US7649083B2Hepatocyte growth factor (HGF) binding antibodyAVEO PHARMACEUTICALS INC·Filed 2007·Granted Jan 19, 2010·29 cites·9 claims
- 0293US7659378B2Hepatocyte growth factor (HGF) binding antibodyAVEO PHARMACEUTICALS INC·Filed 2007·Granted Feb 9, 2010·17 cites·7 claims
- 0392US9175076B2Anti-GDF15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2013·Granted Nov 3, 2015·16 cites·11 claims
- 0491US11725047B2Anti-GDF-15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2020·Granted Aug 15, 2023·2 cites·20 claims
- 0591US9879083B2Anti-Notch3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2013·Granted Jan 30, 2018·12 cites·23 claims
- 0691US9725505B2Methods of treatment using anti-GDF15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2015·Granted Aug 8, 2017·9 cites·36 claims
- 0789US10745476B2Anti-NOTCH3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2018·Granted Aug 18, 2020·5 cites·28 claims
- 0889US7935502B2Hepatocyte growth factor (HGF) binding proteinsAVEO PHARMACEUTICALS INC·Filed 2009·Granted May 3, 2011·7 cites·12 claims
- 0986US12486332B2Anti-ERBB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2023·Granted Dec 2, 2025·0 cites·15 claims
- 1086US12258391B2Anti-GDF-15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2023·Granted Mar 25, 2025·0 cites·18 claims
- 1186US10597444B2Anti-GDF15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2017·Granted Mar 24, 2020·4 cites·9 claims
- 1286US10494441B2Anti-ERBB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2017·Granted Dec 3, 2019·4 cites·7 claims
- 1386US7943344B2Hepatocyte growth factor (HGF) binding proteinsAVEO PHARMACEUTICALS INC·Filed 2009·Granted May 17, 2011·6 cites·11 claims
- 1485US9228021B2Anti-ErbB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2013·Granted Jan 5, 2016·6 cites·39 claims
- 1584US11142573B2Anti-Notch3 antibodyAVEO PHARMACEUTICALS INC·Filed 2017·Granted Oct 12, 2021·2 cites·35 claims
- 1683US7544476B1Identifying cancers sensitive to treatment with inhibitors of notch signalingAVEO PHARMACEUTICALS INC·Filed 2009·Granted Jun 9, 2009·11 cites·9 claims
- 1780US9598498B2Anti-ErbB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2016·Granted Mar 21, 2017·2 cites·24 claims
- 1879US2026053791A1Use of tivozanib to treat subjects with refractory cancerAVEO PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1978US7736861B1Tivozanib response predictionAVEO PHARMACEUTICALS INC·Filed 2009·Granted Jun 15, 2010·5 cites·4 claims
- 2076US9828635B2Predicting tumor response to anti-ERBB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2012·Granted Nov 28, 2017·4 cites·8 claims
- 2176US7615353B1Tivozanib response predictionAVEO PHARMACEUTICALS INC·Filed 2009·Granted Nov 10, 2009·1 cites·6 claims
- 2276US2025275955A1Use of tivozanib to treat subjects with refractory cancerAVEO PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2376US2025277019A1Anti-gdf-15 antibodiesAVEO PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2476US2026035457A1Anti-notch3 antibodyAVEO PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2574US2023295285A1Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agentAVEO PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2673US11680108B2Anti-ErbB3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2019·Granted Jun 20, 2023·0 cites·16 claims
- 2773US9096664B2Nucleic acid encoding hepatocyte growth factor (HGF) binding proteinsAVEO PHARMACEUTICALS INC·Filed 2013·Granted Aug 4, 2015·1 cites·23 claims
- 2873US2025289884A1Anti-notch3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2972US12338282B2Anti-Notch3 antibodyAVEO PHARMACEUTICALS INC·Filed 2021·Granted Jun 24, 2025·0 cites·13 claims
- 3072US2022403015A1Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulatorAVEO PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3170US8373017B2Reconstituted human breast tumor modelAVEO PHARMACEUTICALS INC·Filed 2005·Granted Feb 12, 2013·4 cites·6 claims
- 3269US12269877B2Anti-notch3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2020·Granted Apr 8, 2025·0 cites·18 claims
- 3369US11504365B2Use of tivozanib to treat subjects with refractory cancerAVEO PHARMACEUTICALS INC·Filed 2022·Granted Nov 22, 2022·0 cites·12 claims
- 3468US2025019447A1Combination therapy for treatment of cancerAVEO PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3566US2019292253A1Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agentAVEO PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3664US7556796B2Directed complementationAVEO PHARMACEUTICALS INC·Filed 2006·Granted Jul 7, 2009·2 cites·12 claims
- 3764US2014178934A1Hepatocyte growth factor (hgf) binding proteinsAVEO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3859US8829164B2Anti-ron antibodiesAVEO PHARMACEUTICALS INC·Filed 2013·Granted Sep 9, 2014·0 cites·11 claims
- 3959US2013165343A1Identification of multigene biomarkersAVEO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4058US11897948B2Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulatorAVEO PHARMACEUTICALS INC·Filed 2018·Granted Feb 13, 2024·0 cites·27 claims
- 4158US2013165337A1Identification of multigene biomarkersAVEO PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 4257US2019292251A1Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulatorAVEO PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4356US2014045715A1Tivozanib response predictionAVEO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4454US2022000858A1Use of tivozanib to treat subjects with refractory cancerAVEO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4553US2017306008A1Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agentAVEO PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4653US2013288305A1Anti-fgfr2 antibodiesAVEO PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4751US7622630B2Chimeric cancer modelsAVEO PHARMACEUTICALS INC·Filed 2004·Granted Nov 24, 2009·1 cites·6 claims
- 4847US2017137505A1Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulatorAVEO PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4945US2018195120A1Predicting tumor response to anti-erbb3 antibodiesAVEO PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 5042US2017137506A1Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulatorAVEO PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when AVEO PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →